PortfoliosLab logo
Palisade Bio, Inc. (PALI)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US6963891055

CUSIP

696389105

IPO Date

Dec 20, 2006

Highlights

Market Cap

$3.82M

EPS (TTM)

-$6.07

Gross Profit (TTM)

-$1.00K

EBITDA (TTM)

-$13.21M

Year Range

$0.60 - $5.15

Target Price

$10.67

Short %

3.67%

Short Ratio

0.51

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Palisade Bio, Inc.

Popular comparisons:
PALI vs. MCRB
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

Palisade Bio, Inc. (PALI) returned -58.35% year-to-date (YTD) and -84.76% over the past 12 months. Over the past 10 years, PALI returned -75.81% annually, underperforming the S&P 500 benchmark at 10.85%.


PALI

YTD

-58.35%

1M

-9.04%

6M

-71.60%

1Y

-84.76%

3Y*

-87.86%

5Y*

-82.46%

10Y*

-75.81%

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of PALI, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-17.58%-39.04%-17.88%14.00%-11.44%-58.35%
20241.61%-32.94%-0.72%0.73%-20.07%-6.64%-12.89%-9.95%0.57%-23.38%-9.56%-32.93%-81.36%
2023-44.23%-25.52%62.96%-54.83%-16.98%28.79%32.94%-69.83%-14.64%-4.64%12.61%-5.60%-88.65%
2022-7.69%-23.33%15.22%-26.42%-32.90%-22.03%-5.32%-57.87%-39.19%-7.98%-14.60%33.68%-92.00%
202167.05%-8.84%26.87%-25.39%-49.93%6.82%-28.01%-4.10%-5.69%3.40%-14.96%-44.21%-75.38%
202017.17%-19.91%-28.73%6.81%30.09%-21.74%12.43%-14.79%-15.63%-3.35%15.56%35.38%-11.11%
201937.34%9.16%-5.35%13.44%-11.51%-34.08%-62.59%-22.27%-2.34%-8.98%-43.09%14.45%-84.19%
20186.40%-17.49%9.27%0.00%1.43%-33.68%1.80%7.96%-12.30%-45.43%-13.86%-37.75%-81.80%
2017-15.87%54.85%14.04%-10.23%-5.91%29.82%-73.23%-23.23%10.92%-8.33%-5.79%50.88%-51.61%
2016-8.74%9.58%-12.25%-20.00%-44.17%-13.13%-18.63%20.35%12.28%-18.13%7.10%-2.57%-68.01%
20150.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
20140.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PALI is 5, meaning it’s performing worse than 95% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of PALI is 55
Overall Rank
The Sharpe Ratio Rank of PALI is 1010
Sharpe Ratio Rank
The Sortino Ratio Rank of PALI is 11
Sortino Ratio Rank
The Omega Ratio Rank of PALI is 33
Omega Ratio Rank
The Calmar Ratio Rank of PALI is 33
Calmar Ratio Rank
The Martin Ratio Rank of PALI is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Palisade Bio, Inc. (PALI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Palisade Bio, Inc. Sharpe ratios as of May 30, 2025 (values are recalculated daily):

  • 1-Year: -0.79
  • 5-Year: -0.58
  • 10-Year: -0.56
  • All Time: -0.53

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Palisade Bio, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Palisade Bio, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Palisade Bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Palisade Bio, Inc. was 100.00%, occurring on Apr 3, 2025. The portfolio has not yet recovered.

The current Palisade Bio, Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Jun 25, 20123213Apr 3, 2025
-6.4%Mar 5, 20091Mar 5, 20091Mar 6, 20092
-4.06%Jun 19, 20121Jun 19, 20122Jun 21, 20123
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Palisade Bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Palisade Bio, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 42.0% positive surprise.


-20.00-10.000.0010.0020.0020212022202320242025
-0.47
-0.81
Actual
Estimate

Valuation

The Valuation section provides an overview of how Palisade Bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for PALI relative to other companies in the Biotechnology industry. Currently, PALI has a P/S ratio of 14.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for PALI in comparison with other companies in the Biotechnology industry. Currently, PALI has a P/B value of 0.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items